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ABSTRACT
Introduction In addition to tau pathology and 
neuronal loss, neuroinflammation occurs in progressive 
supranuclear palsy (PSP). However, the prognostic 
value of the in vivo imaging markers for these 
processes in PSP remains unclear. We test the primary 
hypothesis that baseline in vivo imaging assessment of 
neuroinflammation in subcortical regions predicts clinical 
progression in patients with PSP.
Methods Seventeen patients with PSP–Richardson’s 
syndrome underwent a baseline multimodal imaging 
assessment, including [11C]PK11195 positron emission 
tomography (PET) to index microglial activation, [18F]AV-
1451 PET for tau pathology and structural MRI. Disease 
severity was measured at baseline and serially up to 4 
years with the Progressive Supranuclear Palsy Rating 
Scale (PSPRS) (average interval of 5 months). Regional 
grey- matter volumes and PET ligand binding potentials 
were summarised by three principal component analyses 
(PCAs). A linear mixed- effects model was applied to 
the longitudinal PSPRS scores. Single- modality imaging 
predictors were regressed against the individuals’ 
estimated rate of progression to identify the prognostic 
value of baseline imaging markers.
Results PCA components reflecting neuroinflammation 
and tau burden in the brainstem and cerebellum 
correlated with the subsequent annual rate of 
change in the PSPRS. PCA- derived PET markers of 
neuroinflammation and tau pathology correlated with 
regional brain volume in the same regions. However, 
MRI volumes alone did not predict the rate of clinical 
progression.
Conclusions Molecular imaging with PET for microglial 
activation and tau pathology can predict clinical 
progression in PSP. These data encourage the evaluation 
of immunomodulatory approaches to disease- modifying 
therapies in PSP and the potential for PET to stratify 
patients in early phase clinical trials.
INTRODUCTION
Neuroinflammation has been recognised as a 
common pathogenic process in progressive supra-
nuclear palsy (PSP)1 2 and other tauopathies such 
as Alzheimer’s disease3 (AD) and frontotemporal 
dementia,4–6 together with genetic, epidemiolog-
ical and imaging associations. For example, acti-
vated microglia are found in the neighbourhood of 
neurofibrillary tangles, even during early stages of 
disease,1 and are directly synaptotoxic.3 Neuroin-
flammation, including microglial activation, inter-
acts with tau pathology to promote cell dysfunction 
and death in preclinical models of tauopathy.
Positron emission tomography (PET) radioli-
gands have been developed to assess neuroinflam-
mation and tau pathology accumulation in vivo in 
clinical cohorts. [11C]PK11195 is a widely used PET 
tracer that binds primarily to activated microglia in 
PSP7–9 and other neurodegenerative disorders.10 11 
The ligand [18F]AV-1451 is widely used to assess 
tau pathology in AD and can be informative in PSP 
(see12 for review) despite lower sensitivity to PSP tau 
isoforms and off- target binding in some regions.13 14 
However, it has not been shown whether either of 
these PET biomarkers of neuroinflammation and 
tau pathology predict longitudinal clinical progres-
sion in patients with PSP.
Our main hypothesis was that inflammation in the 
subcortical regions associated with PSP pathology 
promotes disease progression. We therefore test 
whether baseline in vivo measures of neuroinflam-
mation ([11C]PK11195 PET) predict the annual rate 
of clinical progression in patients with PSP–Rich-
ardson’s syndrome. We test secondary hypotheses 
regarding the predictive value of baseline cortical 
inflammation, tau pathology ([18F]AV-1451 PET) 
and regional brain volume (structural MRI).
METHODS
Participants
As part of the Neuroimaging of Inflammation in 
Memory and Other Disorders study,15 we recruited 
17 people with a clinical diagnosis of probable PSP 
according to Movement Disorder Society (MDS) 
1996 criteria.16 These participants also met the 
later MDS- PSP 2017 criteria for PSP–Richard-
son’s syndrome.17 Participants underwent a base-
line neuropsychological assessment followed by an 
MRI scan and two PET scans with [11C]PK11195 
(11C- labelled R- enantiomer of PK11195) and [18F]
AV-1451 (also known as 18F- flortaucipir). The 
cross- sectional baseline data of [11C]PK11195 
and [18F]AV-1451 have been published.7 Disease 
severity was measured at baseline visit and serially 
up to 4 years using the Progressive Supranuclear 
Palsy Rating Scale (PSPRS).18 Assessments were at 
an average of 5- month intervals (SD±2.3 months). 
Postmortem confirmation of PSP pathology was 
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available in each of the eight patients who subsequently donated 
their brain to the Cambridge Brain Bank. For all 17 participants, 
the clinical diagnosis was reviewed and confirmed at follow- up.
MRI and PET data acquisition and preprocessing
Full details of the imaging protocols have been published else-
where.9 19 In brief, patients underwent 3 T MRI, together with 
dynamic PET imaging of [11C]PK11195 and [18F]AV-1451 for 
75 and 90 min, respectively. MP- RAGE (Magnetization Prepared 
Rapid Acquisition Gradient Echo) T1- weighted MRI was 
acquired on Siemens Magnetom Tim Trio and Verio scanners 
(Siemens Healthineers, Erlangen, Germany), while PET scans 
were performed on a GE Advance and GE Discovery 690 PET/
CT (GE Healthcare, Waukesha, USA). The two PET scanners 
used identical emission data acquisition protocols and image 
reconstruction algorithms (see Malpetti et al for discussion and 
more details7). Each patient underwent both [11C]PK11195 
and [18F]AV-1451 PET scans using the same scanner (n=11 GE 
Discovery scanner, n=6 GE Advance scanner).7 Median (mean 
and SD) of the time interval between the baseline clinical assess-
ment and the imaging scans were 0.0 (1.1±1.5) months for MRI, 
2.0 (2.7±2.0) months for [11C]PK11195 PET and 1.0 (1.9±1.8) 
months for [18F]AV-1451 PET.
For each subject, the aligned dynamic PET image series for each 
scan was rigidly coregistered to the T1- weighted MRI image. 
Grey- matter volumes and non- displaceable binding potential 
(BPND) values for each tracer were calculated in 83 cortical and 
subcortical regions of interest (ROIs) using a modified version 
of the Hammersmith atlas ( www. brain- development. org), which 
includes parcellation of the brainstem and cerebellar dentate 
nucleus. Each T1 image was spatially normalised using Advanced 
Normalization Tools (http://www. picsl. upenn. edu/ ANTS/), and 
the inverse transform was applied to a version of the Hammer-
smith atlas to bring ROIs to native T1 space. The T1- weighted 
images were segmented into grey matter, white matter and 
cerebrospinal fluid (CSF) with SPM12 ( www. fil. ion. ucl. ac. 
uk) and were used to determine regional grey matter, white 
matter and CSF volumes, and to calculate the total intracranial 
volume (TIV=grey matter+white matter+CSF) in each partic-
ipant. Regional grey- matter volumes included in further anal-
yses were corrected for TIV. Prior to kinetic modelling, regional 
PET data were corrected for partial volume effects from the 
CSF by dividing by the mean regional grey- matter plus white- 
matter fraction determined from Statistical Parametric Mapping 
(SPM) segments smoothed to PET spatial resolution. For [11C]
PK11195, supervised cluster analysis was used to determine the 
reference tissue time–activity curve, and BPND values were calcu-
lated in each ROI using a simplified reference tissue model with 
vascular binding correction.20 For [18F]AV-1451, BPND values 
were quantified in each ROI using a basis function implemen-
tation of the simplified reference tissue model,21 with superior 
cerebellar cortex grey matter as the reference region. This cere-
bellar region was selected as reference region given postmortem 
evidence showing minimal tau pathology in PSP (see pathology 
data in Passamonti et al19).
Statistical analyses
Grey- matter volumes and BPND values for each ligand were 
combined across the two hemispheres to derive 43 bilateral 
ROIs,7 9 19 which were next included in separate principal 
component analyses (PCAs) for each imaging modality. Varimax 
rotation was applied in each PCA to maximise interpretability 
and specificity of the resulting components. Components with 
eigenvalues of >1 were retained, explaining >80% of cumula-
tive variance.
A linear mixed model was applied to longitudinal PSPRS scores 
collected from the first research visit to estimate the clinical 
annual rate of change at group level and then extract a patient- 
specific estimate of disease progression. The model included the 
estimation of a random intercept and slope, with time (in years) 
as independent variable and PSPRS scores as dependent variable. 
The effect of time on clinical changes has been also tested via 
likelihood ratio tests of the model described previously against 
the null model without the time effect. Linear mixed- effects 
analyses were performed using R software and lme4 package (R 
Core Team, 2012).
To test whether specific neuroanatomical patterns of grey- 
matter volume, microglial activation and tau pathology predict 
clinical progression, linear regression models were applied with 
the estimated rate of change (slope) as dependent variable, and 
each method- specific PCA component as predictor. First, we 
tested for significant regressions on slope with each modality- 
specific subcortical component as predictor, in accordance with 
our main hypothesis. Then, we explored the predictive value of 
cortical components running separate linear regression analyses 
for each imaging method and component. Age, education and 
sex were included as nuisance covariates. We tested associa-
tions between rate of change of clinical scores, duration from 
symptom onset to the baseline research visit, and the first PSPRS 
score.
Analogous linear regression models were then estimated with 
the intercept of the clinical severity as dependent variable. This 
identifies a cross- sectional association between imaging markers 
and clinical severity at baseline, which was estimated at individual 
level from the linear mixed- effects model on longitudinal PSPRS 
scores. For cross- sectional analyses, we expected to find signif-
icant associations with subcortical imaging components.7 9 22 23
Lastly, the modality- specific subcortical components were 
included in cross- modality Pearson correlations to test for asso-
ciations between the strength of regional volumes, neuroinflam-
mation and tau pathology.
Data availability
Anonymised data may be shared by request to the senior author 
from a qualified investigator for non- commercial use (data 
sharing may be subject to restrictions according to consent and 
data protection legislation).
RESULTS
The demographics and clinical and cognitive variables of our 
sample are summarised in table 1. Fifteen out of 17 patients 
died within 5 years from the baseline research assessment 
(median=2.5 years, mean±SD=2.2 ± 1.0 (range 0.4–4.5) years 
from baseline visit). Eight of these 15 donated to the Cambridge 
Brain Bank, where post mortem examination confirmed PSP 
pathology in all eight. In table 1, we report demographic, clin-
ical characteristics and group comparisons for two subgroups of 
patients, categorised by dividing the group along the median of 
time interval between study baseline and death. Age, years of 
education, baseline PSPRS and annual PSPRS rate of change were 
compared with independent- samples t- tests; sex was compared 
using χ2 test.
PCA of imaging data
For grey- matter volumes, seven components were identified, 
which explained 80.3% of the total variance. Figure 1 (left 
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panel) provides a pictorial representation of the first four compo-
nents, and online supplemental table 1 details regional weights 
in all seven components. Component 1 was widely distrib-
uted, including medial frontal cortex, thalamus, occipitopari-
etal regions, posterior cingulate cortex and postcentral cortex 
(32.0% of the total variance). Component 2 (11.8% variance) 
was weighted to midbrain, substantia nigra and pons, nucleus 
accumbens and putamen, as well as amygdala, hippocampus and 
precentral cortex, cerebellar grey- matter and dentate nucleus. 
Component 3 (10.0% variance) loaded onto the orbitofrontal 
cortex, anterior temporal lobe and lingual gyrus. Component 4 
(7.9% variance) included the superior temporal gyrus, fusiform 
gyrus, middle inferior temporal lobe and insula.
For [11C]PK11195 BPND and [
18F]AV-1451 BPND, each PCA 
identified four components, which collectively and respectively 
explained 81.4% and 81.8% of the data variance, as reported 
in Malpetti et al.7 For [11C]PK11195 (figure 1, middle panel; 
online supplemental table 2), component 1 loaded onto poste-
rior cortical regions, the orbitofrontal cortex and cerebellar grey 
matter; component 2 grouped together medial and superior 
temporal lobes, insula and temporoparietal junction; component 
3 was weighted to brainstem regions (ie, midbrain and pons), 
dentate nucleus and cerebellar white matter; while component 4 
included superior and medial frontal regions. For [18F]AV-1451 
(figure 1, right panel; online supplemental table 3), component 
1 reflected global cortical binding; component 2 grouped insula 
and medial temporal lobe regions; component 3 loaded onto 
anterior superior temporal gyrus and frontal subgenual cortex; 
component 4 was weighted towards subcortical areas, including 
midbrain, pons, substantia nigra, thalamus, cerebellar dentate 
nucleus and white matter.
Clinical progression as measured by longitudinal PSPRS
The linear mixed model on longitudinal PSPRS progression after 
baseline, considering the first research visit as baseline, indicated 
a significant effect of time (,ean=6.15 points/year, SD=1.06; 









N 17 9 8
Sex (F/M) 7/10 4/5 3/5 χ2=0.08, p=0.772




















6.2±1.5 6.4±0.7 5.9±2.1 t(15)=0.75, 
p=0.468
Statistics are reported for the total patient group and for subgroups based on 
median split of survival from baseline research assessment to death (median=2.5 
years, mean±SD=2.2±1.0).
PSPRS, Progressive Supranuclear Palsy Rating Scale; t(), t- test.
Figure 1 PCs for grey- matter volume, inflammation and tau pathology. First four PCs for grey- matter volumes (left panel), [11C]PK11195 BPND (middle 
panel) and [18F]AV-1451 BPND (right panel). The colours represent the rotated weights (range: from −1 to 1) of the brain regions for each component. BPND, 
non- displaceable binding potential ; PC, principal component.
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figure 2 and table 1). The model comparison against the null 
model confirmed the significant effect of time (∆χ2=42.61, 
∆df=3, p<0.0001). We also applied an analogous model over 
the whole longitudinal clinical assessment period, including all 
scores available from patients’ initial clinical diagnosis visit to 
their latest clinical visit. This confirmed a similar annual rate of 
change in PSPRS (mean=7.20 points/year, SD=1.18).
Single-modality prediction models
We tested whether imaging markers in subcortical components 
predicted longitudinal PSPRS progression, applying linear 
regression models for each modality- specific subcortical compo-
nents (MRI component 2, [11C]PK11195 component 3 and [18F]
AV-1451 component 4). Correcting for age, education and sex, 
the annual rate of clinical progression was related positively with 
(1) the [11C]PK11195 subcortical component 3 (standardised 
beta=0.624, p=0.023) and (2) the [18F]AV-1451 subcortical 
component 4 (standardised beta=0.840, p=0.003) (figure 3, 
top row). Applying regression models on the slope with single 
cortical components, age, education and sex as predictors, we 
found that no other components had significant correlations 
with the annual rate of clinical progression (p>0.05 after false 
discovery rate (FDR) correction for multiple comparisons). For 
MRI, no component showed an association with clinical rate of 
change (p>0.05 after FDR correction for multiple comparisons). 
The regression model on clinical progression with symptom 
duration as single regressor was not significant (standardised 
beta=−0.06, p=0.822 uncorrected). Similarly, clinical severity 
Figure 2 Clinical severity as measured by the PSPRS over time. Coloured 
lines chart the time course of the PSPRS score in individual patients. 
The black line represents the linear fit at group level. PSPRS, Progressive 
Supranuclear Palsy Rating Scale.
Figure 3 Inflammation and tau PET markers are associated with clinical severity and progression. Significant regression analyses of annual change in 
PSPRS scores (top row) and intercept PSPRS scores (bottom row) against baseline scores for each modality- specific principal component (X axis—residual 
component values corrected for covariates): [11C]PK11195 PET (left panel) and [18F]AV-1451 PET (right panel). Estimated parameters are reported for each 
model with age, education and sex as covariates. PET, positron emission tomography; PSPRS, Progressive Supranuclear Palsy Rating Scale.
5Malpetti M, et al. J Neurol Neurosurg Psychiatry 2021;0:1–7. doi:10.1136/jnnp-2020-325549
Neuro- inflammation
at baseline (PSPRS) was not associated with clinical progression 
(standardised beta=0.33, p=0.196).
We tested whether imaging markers in subcortical components 
were related to baseline variation in disease severity. Across the 
three modality- specific subcortical components, linear regres-
sion models with individual PSPRS intercept scores as the depen-
dent variable, correcting for age, education and sex, indicated 
significant associations with the [11C]PK11195 subcortical 
component #3 (standardised beta=0.755, p=0.002), and [18F]
AV-1451 subcortical component #4 (standardised beta=0.673, 
p=0.019) (figure 3, bottom row). However, there was no signif-
icant association between intercept and any of the grey- matter 
components or cortical PET components (all p>0.05 after FDR 
correction for multiple comparisons). The regression model on 
clinical intercept scores with symptom duration (standardised 
beta=0.43, p=0.086) was not significant.
Intermodality correlations between subcortical imaging 
components
Simple correlations across subjects between MRI and PET 
subcortical components of clinical slope were significant for MRI 
component #2 with [11C]PK11195 component 3 (r=−0.584, 
p=0.014 uncorrected, p=0.014 FDR correction) and [18F]
AV-1451 component 4 (r=−0.626, p=0.007 uncorrected, 
p=0.011 FDR correction). The correlation between [11C]
PK11195 component 3 and [18F]AV-1451 component 4 was also 
significant (r=0.769, p<0.0001 uncorrected, p<0.0001 FDR 
correction).7
DISCUSSION
Our main finding is that subcortical neuroinflammation is asso-
ciated with clinical severity of PSP at baseline, and with faster 
subsequent clinical progression. A similar effect is found for 
estimated subcortical tau pathology, with the caveats related to 
interpreting [18F]AV1451 binding in PSP. The PET markers were 
associated with each other and with structural MRI measures for 
atrophy in the same regions. However, subcortical grey- matter 
volumes were not correlated with subsequent clinical progres-
sion and were not significantly related to clinical severity at 
baseline. Similarly, clinical severity at baseline was not predic-
tive of clinical progression in the following years, suggesting 
that the annual rate of clinical changes is approximately constant 
throughout different stages of disease.
Several studies in PSP have explored the association between 
changes in clinical severity and in vivo neuroimaging markers for 
microglial activation (eg, [11C]PK11195 PET8 9), tau pathology 
(eg, [18F]AV-1451 PET19 22–25) and atrophy (eg, structural 
MRI26–28). This study, however, focusses on the prognostic (or 
predictive) potential of baseline multimodal imaging markers. 
The baseline uptakes of both [11C]PK11195 and [18F]AV-1451 
in PSP- related subcortical regions correlated with the subsequent 
annual rate of change in severity, as measured by PSPRS. Note 
that we are not testing whether the progression of PET markers 
compares with progression of disease severity. The progression 
of [18F]AV-1451 uptake has been compared with MRI- derived 
atrophy progression,29 revealing greater atrophy changes than 
PET signal changes over time. Instead, for prognostic value, we 
found that grey- matter volumetric measures were weaker predic-
tors than PET markers, despite the correlation of subcortical grey- 
matter volumes with [11C]PK11195 and [18F]AV-1451 binding. 
The latter correlation suggests a close relationship between not 
only microglial activation and tau pathology,1 7 but also with 
neurodegeneration in those subcortical regions commonly 
associated with pathological hallmarks of PSP.30 Our findings 
align with studies of AD, another tauopathy, in which baseline 
in vivo PET markers of tau pathology and microglial activation 
predicted clinical progression, outperforming structural MRI.31
The correlation of in vivo PET measures with baseline disease 
severity has been reported in previous studies.7 9 22 23 Using [11C]
PK11195 PET to assess neuroinflammation, a study reported a 
positive association was observed between clinical severity and 
ligand binding in pallidum, midbrain and pons.9 There was a 
strong association between [11C]PK11195 binding and [18F]
AV-1451 in these subcortical regions, although inconsistent 
findings are reported in studies using [18F]AV- 1451in PSP (see 
Leuzy et al12). The sporadic lack of significant correlates of [18F]
AV-1451 in PSP is often attributed to the low affinity of the 
ligand for 4R- tau pathology. However, in relatively small studies, 
sessional variance of clinical rating scales may also reduce power. 
Therefore, our estimate of baseline clinical severity used the 
intercept extracted from the linear mixed- effects model of longi-
tudinal PSPRS scores rather than single baseline assessment.
The null result for structural MRI predictors might be 
surprising, given previous reports on the utility of visual and 
volumetric atrophy assessments in the midbrain and other 
subcortical regions, including caudate, putamen, globus pallidus, 
subthalamus and thalamus, as an in vivo biomarker in patients 
with PSP.32 Indeed, structural MRI has provided the most 
studied and validated diagnostic biomarkers in PSP. However, a 
biomarker’s properties for diagnostics (ie, presence of PSP32 33) 
or correlates of severity (ie, at baseline) do not imply the prop-
erty of prognostication.
Overall, our findings on the in vivo association between 
imaging markers of different pathological processes and their 
prognostic relevance accord with postmortem data1 2 and 
suggest a key role for microglial activation and tau burden on 
neurodegeneration, and consequent clinical progression. A 
growing literature supports a role for neuroinflammation in 
driving tau spreading and neurodegeneration in tauopathies (see 
Vogels et al3 for review). Furthermore, genome- wide associa-
tion studies implicate inflammatory pathways in the aetiology 
of tauopathies.34 35 For example, Jabbari et al reported an asso-
ciation between a common variation at the leucine- rich repeat 
kinase 2 (LRRK2) locus and survival from symptom onset to 
death in patients with PSP.35 This relationship may be mediated 
by the effect of increased LRRK2 expression in microglia proin-
flammatory responses,36 promoting spread and accumulation 
of misfolded tau protein, analogous to AD.3 This hypothesis is 
supported by the association of dysregulated expression of the 
microglial- related gene CXCR4, regional accumulation of neuro-
fibrillary tangles and increased risk of PSP.37 The role of early 
neuroinflammation in tauopathies is supported by PET evidence 
of microglial activation preceding PET evidence of aggregated 
tau and symptoms in carriers of mutations of the microtubule 
associated protein tau gene (MAPT).5 A preliminary study of 
longitudinal changes in microglial activation in two patients with 
PSP showed stable microglial activation across 6–10 months8 
but may have lacked power. However, preclinical evidence with 
PET in tau transgenic mice suggests that inflammation increases 
longitudinally and predicts greater tau accumulation and lesser 
performance over time.38
There are several limitations to our study. We recruited 
according to clinical diagnostic criteria, and although clinico-
pathological correlations of PSP- Richardson’s syndrome are 
very high, including 8 of 8 cases in our study with post mortem 
pathology, they are not perfect. Moreover, the average rate of 
change in severity was 6–7 points per year on the PSPRS, which 
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is lower than several previous observational studies18 39 and clin-
ical trials.40 41 This may partially be due to selection criteria that 
favoured patients robust enough to undergo three brain scans at 
baseline. However, our cases were otherwise typical, and 15 out 
of 17 died within 5 years from baseline (mean 2.2 years±1.0). 
The modest size of our cohort prevented the application of 
complex models for the direct comparison between MRI and 
PET predictors, such as multiple linear regression or linear 
mixed models with several independent variables. The replica-
tion of these findings with larger and multicenter clinical cohorts 
will be important to establish generalisability of our results. 
Other limitations relate to the PET tracers used. [11C]PK11195 
binds to the 18 kDa translocator protein which is overexpressed 
in activated microglia, but also in other cell types, like astrocytes 
and vascular smooth muscle cells, although it has been found 
selective for activated microglia over reactive astrocytes.42 There 
are also caveats for [18F]AV-1451, namely, its off- target binding 
(monoamine oxidase, choroid plexus and neuromelanin) and 
lower affinity for PSP tau compared with AD- related tau (see 
Malpetti et al and Leuzy et al7 12 for discussion regarding limita-
tions of this ligand). Nonetheless, the topological distribution 
of [18F]AV-1451 binding and correlations with severity maintain 
utility for this ligand even in PSP.
In conclusion, our results support the relevance of neuroin-
flammation for progression of PSP–Richardson’s syndrome. We 
suggest that [11C]PK11195 may be a valuable biomarker for clin-
ical trials in PSP, complementary to structural MRI. The PET 
markers may be useful for stratification of patients based on 
prognosis and for evaluation of therapeutic response, supporting 
the development of immunomodulatory strategies for disease- 
modifying treatments in PSP, alone or in conjunction with treat-
ments directed against tau and other pathogenic pathways.
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